Lung cancer surgery risks under the microscope: 1,000 patients studied
NCT ID NCT07401498
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks 1,000 people with advanced non-small cell lung cancer who are having surgery to remove lymph nodes. The goal is to see how often complications like nerve damage or bleeding happen and what factors make them more likely. By understanding these risks, doctors hope to make surgery safer in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help surgeons predict and reduce complications from lymph node removal in lung cancer surgery.
- What could go wrong
- This is an observational study, not testing a new treatment. It may not lead to immediate changes in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years. * Clinical stage IA-IIIB NSCLC (TNM 8th edition), oncologically radical resection is planned: anatomical segmentectomy/lobectomy/bilobectomy/pneumonectomy (including sleeve resection). * LND (systematic) is performed with mandatory inclusion of group 7 (subcarinal) lymph nodes. * Signed informed consent from all study patients. Exclusion Criteria: * Small cell lung cancer, benign and metastatic tumors. * "Wedge" surgery without any lymph node dissection. * Nonemergency surgery; conversion is acceptable. * Patients who cannot complete 30 days of observation (no contact, etc.) should be excluded prior to surgery.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced non-small cell lung cancer (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Regional Clinical Oncology Dispensary
Ulyanovsk, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart cancer therapy: tailoring lung cancer treatment with a simple blood test
- New drug cocktail targets tough lung cancer
- Blood test could speed up lung cancer treatment decisions
- New drug duo takes on advanced lung cancer
- Could a common antioxidant boost chemo for advanced lung cancer?
- New study aims to ease pain after breast cancer surgery